Has anyone here tried the Vesilute peptide? I have had bladder issues since transitioning to menopause and I am thinking of trying it.

Every industry has defining moments the ones that separate hype from principle and reveal who’s truly here for the long game. This is one of those moments for ours, and I want to be completely transparent about where we stand. Biomed Industries is the company credited with discovering Bioglutide (NA-931) and developing it as a next-generation GLP-based compound. Our raw materials came from the same supplier Biomed reportedly uses. Recently, serious accusations have surfaced against Biomed claims of fraudulent data, lack of publicly verifiable sequence information, and the absence of a disclosed CAS number or molecular structure. The accuser has raised valid scientific concerns that deserve to be addressed. At the same time, these allegations are new, and Biomed has not yet had the opportunity to publicly respond. That’s why we are pausing not panicking. Even in moments like this, our safeguards remain strong. We can fully document purity through HPLC and LC-MS, confirm sterility and endotoxin levels, and provide verified Certificates of Analysis. However, without a public reference structure or sequence, no lab including ours can confirm 100% molecular identity. We can verify that a compound is clean, sterile, and potent, but we can’t compare it to a molecule that’s never been fully published. To give some context, CB4211 is a great example of how innovation often moves faster than public documentation. This compound, developed for mitochondrial health and metabolic optimization, has been prescribed by physicians and compounded by pharmacies despite its structure, sequence, and CAS never being publicly released. That doesn’t make it ineffective or illegitimate it simply illustrates that, just like Bioglutide, the available data can only go so far. In both cases, these products are sourced, tested, and manufactured to the highest standards, with thorough purity and safety testing but without full structural transparency. That means identity and uniqueness are established through trust, testing, and outcomes rather than public disclosure. For all we know, CB4211 could be a more advanced form or reformulated analog of MOTS-c—or perhaps just a more expensive version under a new label. Until formal sequencing or patent releases are made public, no one can say for sure. This doesn’t discredit its value; it simply reminds us that in early-stage biotech, certainty often trails behind discovery. That’s why rigorous testing, ethical sourcing, and open communication about what is known and what isn’t are so vital.

The argument that mixed peptides are stable simply because a chromatography test showed high purity after 30 days does not hold up under basic principles of chemistry, molecular biology, or analytical science. The claim relies entirely on HPLC purity results, but HPLC only measures retention time and peak area. It does not prove that the molecular structure of a peptide is unchanged. A peptide can undergo oxidation, racemization, conformational changes, or aggregation and still appear as the same peak on a chromatogram. For example, oxidation of methionine to methionine sulfoxide changes the molecule chemically but often produces little or no shift in retention time. This means a sample can still appear 99% pure on HPLC even though part of the peptide population has been chemically altered. Detecting these types of structural changes requires more advanced techniques such as LC-MS/MS, peptide mapping, circular dichroism, NMR spectroscopy, capillary electrophoresis, or dynamic light scattering. None of those analyses were performed, so the conclusion that the peptides remained fully intact cannot be supported. Another major issue is the chemistry of copper and oxidation. When a copper-containing peptide such as GHK-Cu is mixed with other peptides, copper ions can catalyze oxidative reactions. Copper can participate in redox cycling that produces reactive oxygen species, which can oxidize amino acid side chains such as methionine, cysteine, tryptophan, tyrosine, and histidine. Methionine oxidation in particular is one of the most well-known stability problems in peptide drug formulation and pharmaceutical companies spend enormous resources preventing it. Even very small amounts of copper can catalyze these reactions, and the changes they produce may not be visible on a standard purity test. There is also the issue of peptide aggregation, which is governed by basic protein physics. Peptides in solution do not exist as isolated molecules. They constantly interact with water and with each other through hydrophobic interactions, electrostatic interactions, hydrogen bonding, and metal-mediated coordination. When multiple peptides are placed in the same solution, these interactions can create oligomers, aggregates, or misfolded complexes. Aggregation can dramatically change biological activity and receptor binding, yet aggregated peptides often still appear pure during chromatography testing because the test does not necessarily distinguish between properly folded and aggregated structures.

How are we dosing glutathione?

Had a good leg day ( or atleast I thought) with the usual soreness , however 2 days later , I started experiencing a bit of nerve pain in my right glute - about a 2/3 on a scale of 10. Started Implemented more stretching & thought I was out of the woods until pain started shooting down my leg to my calf. With muscle relaxers and prednisone, the inflammation is down some - I’ve started a rigorous protocol with KLOW, BPC 157 & ARA 290. Can the group offer any other suggestions? Thanks in advance